[Improved survival rates in Hodgkin's disease]. 1988

N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
Dept. of Radiology, Faculty of Med. Kyushu Univ.

Results of treatment of 25 Hodgkin's disease patients at Kyushu University Hospital from 1981 to 1985 were reviewed. Total nodal irradiation or MOPP chemotherapy was used mainly. The actuarial 5-year survival rate, 87.2%, was significantly better than the 41.0% of 61 patients treated between 1966 and 1980 (P less than 0.01). However, 12 of the 24 patients in remission eventually relapsed. To further improve the survival rates of patients with Hodgkin's disease, technical improvements in total nodal irradiation and altering Adriamycin-containing chemotherapy protocol from MOPP chemotherapy are advisable.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388

Related Publications

N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
May 1976, Cancer,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
May 1979, Harefuah,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
January 2004, Asian Pacific journal of cancer prevention : APJCP,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
May 1973, National Cancer Institute monograph,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
May 1981, Deutsche medizinische Wochenschrift (1946),
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
June 2016, Cancer medicine,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
March 1963, British journal of cancer,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
December 1965, British medical journal,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
October 2014, Journal of perioperative practice,
N Hayabuchi, and K Jingu, and M Miyoshi, and H Hirata, and K Masuda, and T Shibuya, and J Nishimura, and S Komiyama, and E Ishii, and M Kikuchi
September 1990, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!